← All trials
NCT04720378
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 30, 2021
- Primary completion
- Mar 31, 2022
- Completion date
- Mar 31, 2022
- First posted
- Jan 22, 2021
- Last posted
- Sep 24, 2021
- Enrollment
- 12
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Noveome BiotherapeuticsLead sponsor
- IQVIACollaborator
- Noveome BiotherapeuticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.